Published in Fed Proc on May 15, 1983
Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest (1997) 1.82
c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med (1992) 1.51
Bronchoalveolar mast cells in extrinsic asthma: a mechanism for the initiation of antigen specific bronchoconstriction. Br Med J (Clin Res Ed) (1985) 1.49
Basophils and allergic inflammation. J Allergy Clin Immunol (2013) 1.29
Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br J Pharmacol (1991) 1.26
Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy (2006) 1.09
New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. Ann N Y Acad Sci (2011) 1.00
Functional heterogeneity in the basophil cell lineage. Adv Immunol (2012) 0.92
Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol (2006) 0.88
Prostaglandin D2 release from human skin mast cells in response to ionophore A23187. Br J Pharmacol (1987) 0.83
Endogenous leukotriene D4 formation during anaphylactic shock in the guinea pig. Proc Natl Acad Sci U S A (1987) 0.79
Calcium and mast cell activation. Br J Clin Pharmacol (1985) 0.77
Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38
Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med (1974) 4.31
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med (1996) 4.03
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51
Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters. J Immunol (1986) 3.41
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA (2001) 3.21
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med (2000) 3.08
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (1997) 2.91
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70
A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol (1994) 2.65
Anaphylaxis. N Engl J Med (1991) 2.53
Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37
A highly sensitive fluorescent micro-assay of H2O2 release from activated human leukocytes using a dihydroxyphenoxazine derivative. J Immunol Methods (1997) 2.35
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med (1974) 2.33
Inhibition of histamine release by histamine controlled by H2 receptor. Nature (1973) 2.19
IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol (1995) 2.18
Immunological aspects of allergic asthma. Annu Rev Immunol (1994) 2.17
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16
Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J (2001) 2.15
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08
Effects of colchicine on IgE-mediated early and late airway reactions. Chest (1995) 2.06
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05
Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest (1975) 2.04
The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther (1975) 2.02
Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest (1972) 1.98
Molecular identification of an IgE-dependent histamine-releasing factor. Science (1995) 1.95
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol (1971) 1.93
Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. Infect Immun (1998) 1.87
Anaphylactic release of thromboxane A2, prostaglandin D2, and prostacyclin from human lung parenchyma. Am Rev Respir Dis (1981) 1.86
Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84
Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells. J Immunol (1999) 1.83
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80
Human lung mast cells: purification and characterization. J Immunol (1982) 1.78
The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78
Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77
The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol (1971) 1.73
Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.72
IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest (1978) 1.71
Predicting worsening asthma control following the common cold. Eur Respir J (2008) 1.70
Basophil "releasability" in patients with asthma. Am Rev Respir Dis (1980) 1.70
Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. J Immunol (1988) 1.68
IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol (1995) 1.68
The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins (1972) 1.67
Characterization of a murine model of allergic pulmonary inflammation. Int Arch Allergy Immunol (1994) 1.66
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy (2001) 1.63
Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol (1973) 1.63
Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med (2001) 1.58
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58
Routine use of penicillin skin testing on an inpatient service. N Engl J Med (1971) 1.58
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54
Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol (2000) 1.52
Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52
In vitro studies of human reaginic allergy. Adv Immunol (1968) 1.50
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48
Arachidonic acid metabolism in purified human lung mast cells. J Immunol (1984) 1.47
Collateral ventilation in man. N Engl J Med (1978) 1.47
Biochemical analysis of initial triggering events of IgE-mediated histamine release from human lung mast cells. J Immunol (1983) 1.47
Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy (2001) 1.46
Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol (2000) 1.46
Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol (1976) 1.45
The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. J Immunol (1975) 1.45
Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest (1985) 1.45